1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

| More on:
Cannabis grows at a commercial farm.

Source: Getty Images

One of the worst-performing TSX stocks in recent years is Aurora Cannabis (TSX:ACB). Shares of the Canadian marijuana giant are currently trading 99% below all-time highs, valuing the company at a market cap of $260 million.

Similar to most other pot producers in Canada, Aurora Cannabis has been impacted by oversupply, cannibalization from a thriving illegal market, high inventory levels, and much more. In the last 12 months, higher interest rates have made it expensive to obtain debt funding, while supply chain disruptions and labour shortages continue to exist.

Let’s see if ACB stock can stage a comeback in 2023.

Why Aurora Cannabis stock is a high-risk investment?

In the five years, prior to marijuana legalization in October 2018, ACB stock returned an emphatic 35,620% to investors. Most analysts were then bullish on the company, which had 15 production facilities, allowing it to produce over 600,000 kilos of cannabis each year. However, in 2022, Canadians consumed less than 400,000 kilos of marijuana.

We can see Aurora Cannabis overestimated demand by a wide margin. The company also aggressively acquired other cannabis operators to increase market share and paid a hefty premium for these purchases. As market sentiment normalized, Aurora Cannabis had to report multi-billion-dollar goodwill write-downs.

Due to an oversupply of marijuana, Aurora Cannabis continues to sell its cannabis products at a massive loss. In the last four fiscal years, its operating losses have surged over $1.2 billion. To offset losses, it has shut down multiple production facilities, lowered its employee count, and increased market share in the higher-margin medical marijuana segment. But it still reported an operating loss of $125.4 million in the last two quarters.

Aurora Cannabis has diluted shareholder wealth several times by raising equity capital to support its cash-burn rates. Between mid-2014 and the end of 2022, its share count has increased from 1.3 million to 341 million.

Analysts expect ACB stock to more than double in the next 12 months. But its weak fundamentals make it a high-risk bet in 2023.

Buy shares of Green Thumb Industries instead

A multi-state operator south of the border, Green Thumb Industries (CNSX:GTII) is valued at a market cap of over $2 billion. The company has expanded its presence from 39 stores in eight states in 2019 to 99 retail outlets in 15 states in 2022. This rapid expansion has enabled Green Thumb to end 2022 with US$1 billion in sales, up from just US$216 million in 2019.

While its Canadian peers are struggling with losses, Green Thumb reported an adjusted net income of US$12 million in the fourth quarter. In fact, it has now reported a positive net income for nine consecutive quarters.

Green Thumb is well positioned to benefit if the U.S. states continue to legalize the consumption of marijuana. Further, if pot is legalized at the federal level in the U.S., you can easily expect shares of Green Thumb to explode.

Armed with $200 million in cash and priced at less than two times trailing sales, GTII stock is a compelling bet for those looking to gain exposure to the cannabis sector. Analysts remain bullish and expect GTII stock to surge over 200% in the next 12 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »